GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: AZN
Overweight

Astrazeneca Plc (NYSE: AZN) upgraded to Overweight by Morgan Stanley

Tuesday,  Dec 1, 2015  12:25 PM ET by Kristen Bailey

Morgan Stanley upgraded Astrazeneca Plc (NYSE: AZN) to Overweight.
Morgan Stanley rated Astrazeneca Plc (NYSE: AZN) to Equal-Weight on 09/07/2012, when the price was $23.37.

AstraZeneca PLC (AstraZeneca) is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. The Company?s product portfolio comprise: Arimidex, Crestor, Nexium, Seroquel and Symbicort. It has operations in various markets, such as China, United Kingdom, Sweden and the United States. It has 26 manufacturing sites in 18 countries. Cardiovascular product pipeline includes Saxagliptin, Dapagliflozin, Atherosclerosis/dyslipidaemia, Thrombosis and Atrial fibrillation. Gastrointestinal pipeline includes life cycle management initiatives. AstraZeneca?s Infection pipeline MedImmune and Dedicated tuberculosis (TB) research. Oncology product pipeline includes Zactima (vandetanib), Zactima (vandetanib), ZD4054 and MedImmune.

Morgan Stanley Investment Research is one of the financial industry's dominant thought leaders in equity and fixed-income investing. Our analysts, economists, and strategists have earned this reputation through timely, in-depth analysis of companies, industries, markets, and the world’s economies. Our teams collaborate to assist Morgan Stanley clients with investment decisions, using cash and derivative instruments across major asset classes and geographies.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy